Short Term Growth in Children With Atopic Dermatitis

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00236106

Enrollment

Registered

2005-10-12

Start date

2005-02-28

Completion date

2005-06-30

Last updated

2005-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

Main objective:to assess short term growth in children with atopic dermatitis during treatment with tacrolimus 0.1% and mometasone furoate 0.1%. A singl blind randomised cross over trial including 20 children. The study consists of 5 periods: run in, treatment(1),wash out, treatment(2) and run out. Each period 14 days where the children will use tacrolimus ointment tvice daily, mometasone furoate once daily or moisturizer (in run in wash out and run out)

Interventions

DRUGtacrolimus ointment 0.1%

DRUGmometasone furoate 0.1%

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

5 Years to 14 Years

Healthy volunteers

Inclusion criteria

age 5-14, atopic dermatitis, normal current growth, Tanner 1, informed consent by the parent or guardian, willing and able to comply with study procedures

Exclusion criteria

Tanner 2-5, treatment of atopic dermatitis with anti-inflammatory agent within 1 week before the first visit, current asthma or rhinoconjunctivitis that requires treatment with glucocorticoids, endocrine diseases, major surgery within 4 weeks prior to visit 1, fever \>39.5 for \>3 days

Design outcomes

Primary

Measure	Time frame
short term growth during treatment compared to run in	—

Secondary

Measure	Time frame
U-EPX	—
U-nTX	—
skin prick test	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026